Table of contents
From the editors
p1 | doi:10.1038/nrc2312
Research Highlights
Immunology: Stalemate | PDF (292 KB)
p3 | doi:10.1038/nrc2301
Tumour suppressors: Crystal clear | PDF (240 KB)
p4 | doi:10.1038/nrc2302
Therapeutics: Smac it to them! | PDF (196 KB)
p4 | doi:10.1038/nrc2305
Cell migration: Follow the leader! | PDF (277 KB)
p5 | doi:10.1038/nrc2298
Epigenetics: Silence of the nucleosomes | PDF (205 KB)
p6 | doi:10.1038/nrc2299
Translation: Switching to cap-independence | PDF (382 KB)
p6 | doi:10.1038/nrc2303
In the news
A vast incredulity? | PDF (75 KB)
p6 | doi:10.1038/nrc2308
In brief
Targeted therapeutics | Targeted therapeutics | Metabolism | Metastasis | PDF (95 KB)
p7 | doi:10.1038/nrc2307
Tumour suppressors: Keeping Trim | PDF (350 KB)
p8 | doi:10.1038/nrc2300
Therapeutics: Attacked from all sides | PDF (300 KB)
p8 | doi:10.1038/nrc2304
Tumorigenesis: Keeping a good thing down | PDF (273 KB)
p8 | doi:10.1038/nrc2306
In brief
Angiogenesis | Nanotechnology | MicroRNA | PDF (93 KB)
p9 | doi:10.1038/nrc2309
Reviews
The anaplastic lymphoma kinase in the pathogenesis of cancer
Roberto Chiarle, Claudia Voena, Chiara Ambrogio, Roberto Piva & Giorgio Inghirami
p11 | doi:10.1038/nrc2291
The receptor tyrosine kinase anaplastic lymphoma kinase (ALK) was first identified as part of a chromosomal translocation associated with some anaplastic large cell lymphomas (ALCLs). Now data are emerging that indicate that ALK might be a valid therapeutic target in ALCL and that it could also be involved in other cancers.
Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer
Peter Karran & Natalie Attard
p24 | doi:10.1038/nrc2292
Thiopurines are effective anti-inflammatory, anticancer and immunosuppresive drugs. However, azathioprine is also a carcinogen. So, how do thiopurines exert their therapeutic and carcinogenic effects?
The properties of high-dimensional data spaces: implications for exploring gene and protein expression data
Robert Clarke, Habtom W. Ressom, Antai Wang, Jianhua Xuan, Minetta C. Liu, Edmund A. Gehan & Yue Wang
p37 | doi:10.1038/nrc2294
High-dimensional genomic and proteomic data are now commonplace in cancer research. This Review aims to help biologists understand the properties of high-dimensional data spaces and how these affect our ability to derive meaningful information from the data.
Perspectives
Article series: Hypoxia and metabolism
Opinion
The interplay between MYC and HIF in cancer
Chi V. Dang, Jung-whan Kim, Ping Gao & Jason Yustein
p51 | doi:10.1038/nrc2274
This Perspective considers the differences between the hypoxia-inducible factor (HIF)–MYC transcriptional network that operates under normal homeostatic conditions and the network that operates in a tumorigenic milieu.
Article series: Hypoxia and metabolism
Opinion
A microenvironmental model of carcinogenesis
Robert A. Gatenby & Robert J. Gillies
p56 | doi:10.1038/nrc2255
The authors propose a model of carcinogenesis that identifies microenvironmental barriers that have to be overcome before cancer can become invasive. These adaptations lead to the hallmarks of the malignant phenotype.
Opinion
Survivin, cancer networks and pathway-directed drug discovery
Dario C. Altieri
p61 | doi:10.1038/nrc2293
In the past 10 years, much has been learned about the biology of the inhibitor of apoptosis protein survivin and its expression and roles in cancer. Does survivin function as a nodal protein in cancer networks, and does this make it a promising therapeutic target?
Erratum: Innovations in image-guided radiotherapy
Dirk Verellen, Mark De Ridder, Nadine Linthout, Koen Tournel, Guy Soete & Guy Storme
p71 | doi:10.1038/nrc2310
Correspondence
Correspondence: Peripheral neurotoxicity of platinum-based chemotherapy
Guido Cavaletti
| doi:10.1038/nrc2167-c1
